About | Free Trial

Last Update

2016-03-31T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Jinsy Andrews?

Dr. Jinsy Andrews A. MD

Senior Director, Clinical Research and Development and Head of Neuromuscular Therapeutics

Cytokinetics , Incorporated

Direct Phone: (650) ***-****       

Email: j***@***.com

Cytokinetics , Incorporated

280 East Grand Avenue

South San Francisco, California 94080

United States

Company Description

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. A... more

Find other employees at this company (166)

Background Information

Employment History

History of the Spastic Paraplegia Foundation

Co-Director, MDA and ALS Clinic

Hospital for Special Care

Co-director, Department of Neuromuscular Medicine

MDA/ALS RESEARCH CENTER

Affiliations

ALS Fellow
Eleanor and Lou Gehrig MDA/ALS Research Center

Education



Albany Medical College



Mailman School of Public Health

B.S.

Union College

M.D.

Albany Medical College

M.D.

Columbia University

MSc

Web References (57 Total References)


"This unique collaboration between ...

www.biospace.com [cached]

"This unique collaboration between Origent Data Sciences, Cytokinetics and The ALS Association reflects another step in our collective efforts to accelerate the clinical trial process and make new medicines available to people with ALS in desperate need of new therapeutic options," said Jinsy Andrews, M.D., Cytokinetics' Senior Director Clinical Research and Development and Head of Neuromuscular Therapeutics. "We are pleased to join with Origent to potentially validate their predictive model using datasets from BENEFIT-ALS and VITALITY-ALS which we hope may then facilitate the use of this novel technology to positively impact the design and conduct of future ALS clinical trials."Â


"This unique collaboration between ...

www.origent.com [cached]

"This unique collaboration between Origent Data Sciences, Cytokinetics and The ALS Association reflects another step in our collective efforts to accelerate the clinical trial process and make new medicines available to people with ALS in desperate need of new therapeutic options," said Jinsy Andrews, M.D., Cytokinetics' Senior Director Clinical Research and Development and Head of Neuromuscular Therapeutics.


An oral presentation titled "The Effects ...

phx.corporate-ir.net [cached]

An oral presentation titled "The Effects of Tirasemtiv on Measures of Respiratory Function in Amyotrophic Lateral Sclerosis" was presented by Jinsy Andrews, MD, MSc, Director, Clinical Research and Development at Cytokinetics. Dr. Andrews summarized results on measures of respiratory function from BENEFIT-ALS and concluded that tirasemtiv may have had cumulative, longer term pharmacologic effects on Slow Vital Capacity (SVC) and that the effect of tirasemtiv on SVC appeared robust. In BENEFIT-ALS, the effect of tirasemtiv on SVC was similar in magnitude across all subgroups evaluated and was statistically significant within the majority of subgroups evaluated. Dr. Andrews observed that vital capacity is a clinically meaningful measure of disease progression and prognosis and is used to determine major clinical decisions in the treatment of patients with ALS.


An oral presentation titled "The Effects ...

ir.cytokinetics.com [cached]

An oral presentation titled "The Effects of Tirasemtiv on Measures of Respiratory Function in Amyotrophic Lateral Sclerosis" was presented by Jinsy Andrews, MD, MSc, Director, Clinical Research and Development at Cytokinetics. Dr. Andrews summarized results on measures of respiratory function from BENEFIT-ALS and concluded that tirasemtiv may have had cumulative, longer term pharmacologic effects on Slow Vital Capacity (SVC) and that the effect of tirasemtiv on SVC appeared robust. In BENEFIT-ALS, the effect of tirasemtiv on SVC was similar in magnitude across all subgroups evaluated and was statistically significant within the majority of subgroups evaluated. Dr. Andrews observed that vital capacity is a clinically meaningful measure of disease progression and prognosis and is used to determine major clinical decisions in the treatment of patients with ALS.


Jinsy A. Andrews, ...

www.hfsc.org [cached]

Jinsy A. Andrews, M.D.

Neuromuscular Nurse Specialist Phone: (860) 612-6305 Fax: (860) 612-6303 E-mail: ckiely@hfsc.org

Similar Profiles

Other People with this Name

Other people with the name Andrews

Laurie Andrews
JH Land Trust

Jan Andrews
Belfairs Methodist Church

Ericka Andrews
North Florida Child Development , Inc.

Christopher Andrews
Dalhousie University

Alex Andrews
Boulton CRE

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory